AstraZeneca (AZN) and partner Daiichi Sankyo announced that the FDA has accepted their biologics license application (BLA) seeking approval of the antibody drug conjugate, datopotamab deruxtecan (Dato-DXd), for a breast cancer indication.The BLA is seeking approval of Dato-DXd for treating unresectable or metastatic HR+ HER2- breast cancer in patients who have received prior systemic therapy for unresectable or metastatic disease.The FDA is expected to give its decision on the BLA in the first quarter of 20 ...

AstraZeneca (AZN) announced that the FDA had approved Voydeya (danicopan) for treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and chronic blood disorder.Voydeya is a first-in-class oral Factor D inhibitor, which has been approved by the FDA as an add-on to standard-of-care C5 inhibitors, Ultomiris (ravulizumab) or Soliris (eculizumab), for the treatment of extravascular hemolysis in adult patients with PNH. Ultomiris and Soliris are also marketed by AstraZeneca for treating PNH and some other rar ...

In the latest trading session, Astrazeneca (AZN) closed at $67.25, marking a -0.74% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.2%. Meanwhile, the Dow lost 0.6%, and the Nasdaq, a tech-heavy index, added 0.11%.Prior to today's trading, shares of the pharmaceutical had gained 4.88% over the past month. This has outpaced the Medical sector's gain of 2.21% and the S&P 500's gain of 3.32% in that time.Investors will be eagerly watching for the performance of Ast ...

In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step. An important point to note is that stocks can witness price or time correction. This column focuses on stagnating blue-chip stocks (time correction) that can awaken and surge higher.It’s not uncommon for investors to lose interest in stocks that have remained sideways for an extended period. That translates into undervaluation, and the stagnating ...

AstraZeneca (AZN) announced a definitive agreement to acquire Fusion Pharmaceuticals (FUSN) , which will add next-generation radioconjugates, a promising modality in cancer treatment, to its cancer pipeline.AstraZeneca has offered to acquire Fusion, a Canadian company, for a price of $21.00 per share in cash, which represents a premium of 97% to the latter’s closing price of $10.64 on Monday, Mar 18. In addition, AstraZeneca will be entitled to make a non-transferable contingent value (CV) payment of $3.00 ...

The latest trading session saw Astrazeneca (AZN) ending at $65.86, denoting a +0.02% adjustment from its last day's close. This change lagged the S&P 500's 0.57% gain on the day. Meanwhile, the Dow experienced a rise of 0.83%, and the technology-dominated Nasdaq saw an increase of 0.39%.Heading into today, shares of the pharmaceutical had gained 2.46% over the past month, outpacing the Medical sector's gain of 0.13% and lagging the S&P 500's gain of 2.97% in that time.The investment community will be paying ...

AstraZeneca (AZN) announced plans to cap out-of-pocket expenses for its inhaled respiratory portfolio in the United States at $35 per month, following a similar move by rival Boehringer Ingelheim earlier this month.This cap would apply to all of AstraZeneca’s inhaled respiratory products, which include Airsupra, Bevespi Aerosphere, Breztri Aerosphere and Symbicort.However, the company plans not to start this until June 2024. The British drugmaker is one of the biggest sellers of inhalers in the United State ...

Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share. As part of the deal, AZN will gain access to the cancer specialist's most advanced program, FPI-2265, which focuses on prostate cancer. In response, Wedbush cut its rating to "neutral" from "outperform," while Jefferies downgraded the shares to "hold" from "buy," though both firms hiked their price-target hikes. No brokerage in ...

About this content About Ian Lyall Ian Lyall, a seasoned journalist and editor, brings over three decades of experience to his role as Managing Editor at Proactive. Overseeing Proactive's editorial and broadcast operations across six offices on three continents, Ian is responsible for quality control, editorial policy, and content production. He directs the creation of 50,000 pieces of real-time news, feature articles, and filmed interviews annually. Prior to Proactive, Ian helped lead the business outpu ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have emerged as a promising modality in cancer ...